| Medical Tribune, 3 December 2024 ‘It’s a wonderful feeling, when you can present the results of work you’ve been doing for twenty years – and about which many people around you said that it’s complete nonsense. When it turns out, after all these years, that you were right, that’s quite good, isn’t it?!’, says Jaroslav Štěrba. | | CzechCrunch, 14 November 2024 Lenka Bešše, a biologist from NICR, speaks about ways of understanding cellular mechanisms that allow cancer to develop and become more resistant, but also about how very different it is to do research in Switzerland and in Czechia, especially with two small children. | | Žena-IN, 3 November 2024 Cancers of the blood belong among those that can be successfully treated, but there are still many patients whom physicians still cannot help. Science is, however, making fast progress, says the haematologist and researcher Tomáš Stopka, who focuses in NICR on the development of new medications for haematological malignities. | | Zdravotnický deník, 1 November 2024 ‘NICR reacts to pressing needs of the state administration, which needs to see, when it focuses on academic oncology, where research takes place and where it is done well. Otherwise, it can happen that it would spend an endless amount of money that would fragment all around the sphere, but it won’t be actually clear what it’s good for,’ said Pavel Doleček, secretary of the Minister of Science, Research, and Innovation, with appreciation. | | Novinky.cz, 27 October 2024 ‘A basic component of search for new medications for a concrete cancer is an understanding of its biological foundations. We push forward the potential of oncology by focusing not only on the cancer cells as such but study the tumour as a whole. That enables us to influence the processes that take place in it’, explained, among other things, Aleksi Šedo to readers of Novinky.cz. |
|